- Ongoing, recruitingTherapeutic exploratory (Phase II)
ABCSG 45: A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status
This study looks at a new combination treatment for a specific type of early breast cancer. It compares giving a drug called olaparib with carboplatin before surgery, with a standard chemotherapy. The aim is to see if the new treatment shrinks the cancer more effectively.
For: Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)Austria - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
For: Breast CancerUnited States · Australia · Austria - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
For: Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast NeoplasmsUnited States · Argentina · Australia - AuthorisedTherapeutic confirmatory (Phase III)
OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women
This study, OPTIMA YOUNG, is for younger women with a common type of early breast cancer. It looks at the best way to treat this cancer to stop it from coming back, by comparing different medications and how well they work.
Poland · France · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
This study looks at a new way to treat an aggressive type of breast cancer called Triple Negative Breast Cancer (TNBC). It combines a special immune-boosting drug (Pembrolizumab) with standard chemotherapy to see if it can shrink tumours more effectively before surgery and prevent them from returning.
For: Triple Negative Breast Cancer (TNBC)Portugal · Germany · Poland